Evaluation of the TB-Biochip Oligonucleotide Microarray System for Rapid Detection of Rifampin Resistance in Mycobacterium tuberculosis

ABSTRACT The TB-Biochip oligonucleotide microarray system is a rapid system to detect mutations associated with rifampin (RIF) resistance in mycobacteria. After optimizing the system with 29 laboratory-generated rifampin-resistant mutants of Mycobacterium tuberculosis, we evaluated the performance of this test using 75 clinical isolates of Mycobacterium tuberculosis. With this small sample set, the TB-Biochip system displayed a sensitivity of 80% and a specificity of 100% relative to conventional drug susceptibility testing results for RIF resistance. For these samples (∼50% tested positive), the positive predictive value was 100% and the negative predictive value was 85%. Four of the seven observed discrepancies were attributed to rare and new mutations not represented in the microarray, while three of the strains with discrepant results did not carry mutations in the RIF resistance-determining region. The results of this study confirm the utility of the system for rapid detection of RIF resistance and suggest approaches to increasing its sensitivity.

[1]  D. Wilkinson.  Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization, 1997. 228pp. Price Sw. fr 25/US$22.50 (in developing countries Sw. fir 17.50). (Reference WHO/TB/97.229) , 1998 .

[2]  S. Gillespie,et al.  Evolution of Drug Resistance in Mycobacterium tuberculosis: Clinical and Molecular Perspective , 2002, Antimicrobial Agents and Chemotherapy.

[3]  T. Kocagoz,et al.  Rapid Determination of Rifampin Resistance in Clinical Isolates of Mycobacterium tuberculosis by Real-Time PCR , 2005, Journal of Clinical Microbiology.

[4]  A. Mirzabekov,et al.  Evaluation of hybridisation on oligonucleotide microarrays for analysis of drug-resistant Mycobacterium tuberculosis. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  F. Drobniewski,et al.  Comparison of Three Molecular Assays for Rapid Detection of Rifampin Resistance in Mycobacterium tuberculosis , 1998, Journal of Clinical Microbiology.

[6]  A. Mirzabekov,et al.  Identification of Rifampin-Resistant Mycobacterium tuberculosis Strains by Hybridization, PCR, and Ligase Detection Reaction on Oligonucleotide Microchips , 2001, Journal of Clinical Microbiology.

[7]  L. Amaral,et al.  Direct Application of the INNO-LiPA Rif.TB Line-Probe Assay for Rapid Identification of Mycobacterium tuberculosis Complex Strains and Detection of Rifampin Resistance in 360 Smear-Positive Respiratory Specimens from an Area of High Incidence of Multidrug-Resistant Tuberculosis , 2005, Journal of Clinical Microbiology.

[8]  J. Sáez-Nieto,et al.  Molecular analysis of rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996-2001). Description of new mutations in the rpoB gene and review of the literature. , 2003, International journal of antimicrobial agents.

[9]  C. Dye,et al.  Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization, 1997. 228pp. Price Sw. fr 25/US$22.50 (in developing countries Sw. fir 17.50). (Reference WHO/TB/97.229) , 1998 .

[10]  J. Vijg,et al.  Detection of rpoB Mutations Associated with Rifampin Resistance in Mycobacterium tuberculosis Using Denaturing Gradient Gel Electrophoresis , 2005, Antimicrobial Agents and Chemotherapy.

[11]  A. Telenti,et al.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis , 1993, The Lancet.

[12]  T. Shinnick,et al.  National plan for reliable tuberculosis laboratory services using a systems approach. Recommendations from CDC and the Association of Public Health Laboratories Task Force on Tuberculosis Laboratory Services. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[13]  T. Holtz,et al.  Multidrug-resistant Tuberculosis Detection, Latvia , 2005, Emerging infectious diseases.

[14]  J. T. Crawford,et al.  Characterization of Spontaneous, In Vitro-Selected, Rifampin-Resistant Mutants of Mycobacterium tuberculosisStrain H37Rv , 2000, Antimicrobial Agents and Chemotherapy.

[15]  Yi-Jing Chen,et al.  Characterization of rifampicin-resistant Mycobacterium tuberculosis in Taiwan. , 2003, Journal of medical microbiology.

[16]  L. Schouls,et al.  Multicenter evaluation of reverse line blot assay for detection of drug resistance in Mycobacterium tuberculosis clinical isolates. , 2004, Journal of microbiological methods.

[17]  S. Niemann,et al.  Frequency of rpoB Mutations Inside and Outside the Cluster I Region in Rifampin-Resistant Clinical Mycobacterium tuberculosis Isolates , 2001, Journal of Clinical Microbiology.

[18]  F. Kramer,et al.  Rapid Detection of Rifampin Resistance in Mycobacterium tuberculosis Isolates from India and Mexico by a Molecular Beacon Assay , 2004, Journal of Clinical Microbiology.

[19]  Lung Disease,et al.  Anti-tuberculosis drug resistance in the world : the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance , 1997 .

[20]  N. Schluger.  Changing approaches to the diagnosis of tuberculosis. , 2001, American journal of respiratory and critical care medicine.